Immunohistochemical detection of somatostatin receptor types 1-5 in medullary carcinoma of the thyroid.
about
Correlation of monoclonal and polyclonal somatostatin receptor 5 antibodies in pancreatic neuroendocrine tumors.Somatostatins and their role in thyroid cancer.Positron emission tomographic imaging of copper 64- and gallium 68-labeled chelator conjugates of the somatostatin agonist tyr3-octreotate.Antiangiogenic effects of somatostatin analogues.Somatostatin analogs and radiopeptides in cancer therapy.Evaluation of copper-64-labeled somatostatin agonists and antagonist in SSTr2-transfected cell lines that are positive and negative for p53: implications for cancer therapy.(111)In-octreotide scintigraphy for identification of metastatic medullary thyroid carcinoma in children and adolescentsMapping of somatostatin receptor types in GH or/and PRL producing pituitary adenomasReceptor-mediated tumor targeting with radiopeptides. Part 1. General concepts and methods: applications to somatostatin receptor-expressing tumors.Molecular imaging of neuroendocrine tumorsSomatostatin receptors in non-neuroendocrine malignancies: the potential role of somatostatin analogs in solid tumors.Diagnosis and preoperative imaging of multiple endocrine neoplasia type 2: current status and future directions.Cellular signaling pathway alterations and potential targeted therapies for medullary thyroid carcinoma.Colocalization of somatostatin receptors and epidermal growth factor receptors in breast cancer cells.Everolimus is an active agent in medullary thyroid cancer: a clinical and in vitro study.Routine preoperative (111)In-octreotide scintigraphy in patients with medullary thyroid cancer.Expression of a urokinase-type plasminogen activator during tumor growth leads to angiogenesis via galanin activation in tumor-bearing mice.AB3-Loaded and Tumor-Targeted Unimolecular Micelles for Medullary Thyroid Cancer Treatment.Expression of somatostatin mRNA and peptides in C-cell tumours of the thyroid gland in Han Wistar rats.Molecular imaging of advanced thyroid cancer: iodinated radiotracers and beyond.Recent advances in the biology and therapy of medullary thyroid carcinoma.Somatostatin receptor subtype 1 might be a predictor of better response to therapy in medullary thyroid carcinoma.SPECT/CT and PET/CT molecular imaging in medullary thyroid carcinoma. Are we running in the right direction?68Ga-DOTATATE PET/CT in recurrent medullary thyroid carcinoma: a lesion-by-lesion comparison with 111In-octreotide SPECT/CT and conventional imaging.Multimodal imaging with (18)F-FDG-PET/CT and (111)In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma.Role of (68)Ga-DOTATOC PET-CT in the diagnosis and staging of pancreatic neuroendocrine tumours.Bone and Calcified Soft Tissue Metastases of Medullary Thyroid Carcinoma Better Characterized on F-Fluoride PET/CT than on Ga-Dotatate PET/CTInternational Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New NomenclatureComparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinomaEvolving paradigms for successful molecular imaging of medullary thyroid carcinomaThe 2015 Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma: the “evidence-based” refusal to endorse them by EANM due to the “not evidence-based” marginalization of the role of Nuclear Medicine
P2860
Q34511149-4C438975-D025-43B1-8C9B-2939A45FC609Q34626992-0C4621BF-B75C-46E1-A65F-80507E1133EAQ34696158-8047DA28-2E4C-4673-AB0B-6889325462CAQ34920676-0DE8C1C0-A3D0-4120-82B7-2DD904ACFCA6Q34972896-11BA07A7-EF8C-4D70-9EB4-187A6B7F7E86Q35713096-76EA1F49-EBA1-4319-AD52-913FB56B31A6Q35744505-828A4731-CD0F-4A55-8CC4-852EB747309AQ35769837-0F13FC18-F54F-4232-B410-373209F74D85Q36008285-F30877A8-DCA5-486E-A695-D96567B8DC83Q37730951-75B03A5C-FC7D-43F8-B302-BCB873AD2441Q37898112-8D8DEC27-E932-4380-8390-E344112E475BQ38217012-81E06250-6CA7-4833-8805-191EB6BCB198Q41251561-03D9D82A-666E-4876-971A-F359208618F7Q41881505-B6B48141-A6C3-4EC0-A3C9-E2C5E8EE2C19Q42914109-8AE1B107-4546-462F-975C-3BA4B289BFD1Q43876300-DB698306-F897-489B-9157-0190881F5198Q47111162-4EA10661-0FA9-4A11-B271-DC4300965A4FQ47175904-447E42BA-37FB-48F2-BABE-4207815870BBQ47686377-D35D22A9-20FE-454F-BC48-0ED139A788E5Q48098904-6EF26379-8218-4BB2-A465-3FE9A58246A0Q48246978-8F810578-711E-4F8E-8AD3-9FDF3752B8DAQ48289865-A14E9771-2EA8-45F5-BF5B-51AE67E5F8E7Q52939430-BAE9E0AC-8D9C-495E-AF04-89BE14671A14Q52944867-A3C33147-5B45-448E-BFC1-593A67DD7B2AQ52985771-61C7FA71-E371-44EF-9D67-3FFC861D519DQ53214095-F05C053A-F356-424E-B7C5-1BB329E9225CQ56524986-5BA647CD-8434-4B33-A7BD-A787D5D015A4Q57144951-2FC79F25-4F96-4D37-A5AC-CD5FF5643475Q57998575-82A8AA9E-708A-4561-BE6B-98F7FC6879B5Q57998577-6BB3F186-BADE-4C27-AC35-EB4F93F61474Q58005184-40BC8459-1618-4E0C-9EC3-7FBCD4D3F7FB
P2860
Immunohistochemical detection of somatostatin receptor types 1-5 in medullary carcinoma of the thyroid.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Immunohistochemical detection ...... lary carcinoma of the thyroid.
@en
Immunohistochemical detection ...... lary carcinoma of the thyroid.
@nl
type
label
Immunohistochemical detection ...... lary carcinoma of the thyroid.
@en
Immunohistochemical detection ...... lary carcinoma of the thyroid.
@nl
prefLabel
Immunohistochemical detection ...... lary carcinoma of the thyroid.
@en
Immunohistochemical detection ...... lary carcinoma of the thyroid.
@nl
P2093
P2860
P1476
Immunohistochemical detection ...... lary carcinoma of the thyroid.
@en
P2093
P2860
P304
P356
10.1046/J.1365-2265.2001.01175.X
P577
2001-05-01T00:00:00Z